Correlation between chemotype-dependent binding conformations of HSP90α/β and isoform selectivity-Implications for the structure-based design of HSP90α/β selective inhibitors for treating neurodegenerative diseases.

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Bioorganic & Medicinal Chemistry Letters

• Publication date

  Unknown publication date

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1016/j.bmcl.2013.11.036PMID 24332488
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Paralog-selective Hsp90 inhibitors define tumor-specific regulation of HER2.

  2013cited by this paper
• Experimental and structural testing module to analyze paralogue-specificity and affinity in the Hsp90 inhibitors series.

  2013cited by this paper
• Development of a Grp94 inhibitor.

  2012cited by this paper
• EC144 is a potent inhibitor of the heat shock protein 90.

  2012cited by this paper
• A Screen for Enhancers of Clearance Identifies Huntingtin as a Heat Shock Protein 90 (Hsp90) Client Protein*

  2011cited by this paper
• Heat shock protein 90: inhibitors in clinical trials.

  2010cited by this paper
• Preclinical Antitumor Activity of the Orally Available Heat Shock Protein 90 Inhibitor NVP-BEP800

  2010cited by this paper
• Update on Hsp90 inhibitors in clinical trial.

  2009cited by this paper
• Combining hit identification strategies: fragment-based and in silico approaches to orally active 2-aminothieno[2,3-d]pyrimidine inhibitors of the Hsp90 molecular chaperone.

  2009cited by this paper
• Small-molecule modulation of cellular chaperones to treat protein misfolding disorders.

  2009cited by this paper
• NVP-AUY922: a novel heat shock protein 90 inhibitor active against xenograft tumor growth, angiogenesis, and metastasis.

  2008cited by this paper
• SNX2112, a Synthetic Heat Shock Protein 90 Inhibitor, Has Potent Antitumor Activity against HER Kinase–Dependent Cancers

  2008cited by this paper
• Medicinal chemistry of Hsp90 inhibitors.

  2008cited by this paper
• 4,5-diarylisoxazole Hsp90 chaperone inhibitors: potential therapeutic agents for the treatment of cancer.

  2007cited by this paper
• Structures of GRP94-nucleotide complexes reveal mechanistic differences between the hsp90 chaperones.

  2007cited by this paper
• Modulation of Hsp90 function in neurodegenerative disorders: a molecular-targeted therapy against disease-causing protein

  2006cited by this paper
• The HSP90 family of genes in the human genome: insights into their divergence and evolution.

  2005cited by this paper
• Structure of Unliganded GRP94, the Endoplasmic Reticulum Hsp90

  2005cited by this paper
• Development and optimization of a binding assay for the XIAP BIR3 domain using fluorescence polarization.

  2004cited by this paper
• Structure-activity relationships in purine-based inhibitor binding to HSP90 isoforms.

  2004cited by this paper
• Hsp90 isoforms: functions, expression and clinical importance

  2004cited by this paper
• Synthesis of novel fluorescent probes for the molecular chaperone Hsp90.

  2003cited by this paper
• Crystal structure and molecular modeling of 17-DMAG in complex with human Hsp90.

  2003cited by this paper
• Regulation of Signaling Protein Function and Trafficking by the hsp90/hsp70-Based Chaperone Machinery 1

  2003cited by this paper
• Structure of the N-terminal Domain of GRP94

  2003cited by this paper
• Structure, function, and mechanism of the Hsp90 molecular chaperone.

  2001cited by this paper
• Crystal structure of an Hsp90-geldanamycin complex: targeting of a protein chaperone by an antitumor agent.

  1997cited by this paper

• In Vivo Visualization and Quantification of Brain Heat Shock Protein 90 with [11C]HSP990 in Healthy Aging and Neurodegeneration

  2025cites this paper
• The Hsp90β Isoform: An Attractive Target for Drug Development

  2025cites this paper
• Novel N-(4,5,6,7-tetrahydrobenzisoxazol-4-yl)amides as HSP90 inhibitors: design, synthesis and biological evaluation.

  2025cites this paper
• Treatment with Tau fibrils impact Huntington's disease-related phenotypes in cell and mouse models.

  2024cites this paper
• Alchemical approach performance in calculating the ligand-binding free energy

  2024cites this paper
• FRET Assays for the Identification of C. albicans HSP90-Sba1 and Human HSP90α-p23 Binding Inhibitors

  2024cites this paper
• A novel PET probe to selectively image heat shock protein 90α/β isoforms in the brain

  2024cites this paper
• Radiosynthesis and preclinical evaluation of [11C]SNX-ab as an Hsp90α,β isoform-selective PET probe for in vivo brain and tumour imaging

  2023cites this paper
• Identification of Promising Drug Candidates against Prostate Cancer through Computationally-Driven Drug Repurposing

  2023cites this paper
• Is the C-Terminal Domain an Effective and Selective Target for the Design of Hsp90 Inhibitors against Candida Yeast?

  2023cites this paper
• Targeting Borrelia burgdorferi HtpG with a berserker molecule, a strategy for anti-microbial development.

  2023cites this paper
• Selective inhibition of hsp90 paralogs: Uncovering the role of helix 1 in Grp94-selective ligand binding

  2023cites this paper
• Following the design path of isoform-selective Hsp90 inhibitors: Small differences, great opportunities.

  2023cites this paper
• Pan‐HSP90 ligand binding reveals isoform‐specific differences in plasticity and water networks

  2023cites this paper
• Scaffold Hopping and Screening for Potent Small Molecule Agonists for GRP94: Implications to Alleviate ER Stress-Associated Pathogenesis

  2023cites this paper
• Large-Scale Ligand Perturbations of the Protein Conformational Landscape Reveal State-Specific Interaction Hotspots

  2022cites this paper
• HSP90 inhibitors and cancer: Prospects for use in targeted therapies (Review)

  2022cites this paper
• Conformational Analysis of the Loop-to-Helix Transition of the α-Helix3 Plastic Region in the N-Terminal Domain of Human Hsp90α by a Computational Biochemistry Approach

  2022cites this paper
• Pan- and isoform-specific inhibition of Hsp90: Design strategy and recent advances.

  2022cites this paper
• Molecular design of anticancer drugs from marine fungi derivatives

  2021cites this paper
• The Development of Hsp90β-Selective Inhibitors to Overcome Detriments Associated with pan-Hsp90 Inhibition.

  2021cites this paper
• Fungal-Selective Resorcylate Aminopyrazole Hsp90 Inhibitors: Optimization of Whole-Cell Anticryptococcal Activity and Insights into the Structural Origins of Cryptococcal Selectivity.

  2021cites this paper
• Thermodynamic Dissection of Potency and Selectivity of Cytosolic Hsp90 Inhibitors.

  2021cites this paper
• Cell Surface GRP94 as a Novel Emerging Therapeutic Target for Monoclonal Antibody Cancer Therapy

  2021cites this paper
• The significance of resorcinol/resorcylate in the structure of anti-cancer therapeutics targeting Hsp90: Synthesis and structure-activity relationship (SAR) studies

  2021cites this paper
• Design and Synthesis of TRAP1 Selective Inhibitors: H-Bonding with Asn171 Residue in TRAP1 Increases Paralog Selectivity.

  2021cites this paper
• In silico identification of potential Hsp90 inhibitors via ensemble docking, DFT and molecular dynamics simulations

  2021cites this paper
• Prioritization of Molecular Targets for Antimalarial Drug Discovery

  2021cites this paper
• Computational studies of molecular pre-organization through macrocyclization: Conformational distribution analysis of closely related non-macrocyclic and macrocyclic analogs.

  2021cites this paper
• 2-((1-Phenyl-1H-1,2,3-triazol-4-yl)methyl)-2-azabicyclo[3.2.1]octan-3-one derivatives: Simplification and modification of aconitine scaffold for the discovery of novel anticancer agents.

  2020cites this paper
• Modulation of protein fate decision by small molecules: targeting molecular chaperone machinery

  2020cites this paper
• Heat shock protein 90 (Hsp90) Inhibitors: An Update on Achievements, Challenges, and Future Directions.

  2020cites this paper
• Structures of Hsp90α and Hsp90β bound to a purine‐scaffold inhibitor reveal an exploitable residue for drug selectivity

  2019influential citation
• Discovery of 2-((4-resorcinolyl)-5-aryl-1,2,3-triazol-1-yl)acetates as potent Hsp90 inhibitors with selectivity over TRAP1.

  2019cites this paper
• Old and New Approaches to Target the Hsp90 Chaperone.

  2019cites this paper
• Structural basis for species-selective targeting of Hsp90 in a pathogenic fungus

  2019cites this paper
• Design and synthesis of fungal-selective resorcylate aminopyrazole Hsp90 inhibitors.

  2019cites this paper
• NECA derivatives exploit the paralog-specific properties of the site 3 side pocket of Grp94, the endoplasmic reticulum Hsp90

  2019cites this paper
• HSP90 Inhibitors Blocking Multiple Oncogenic Signaling Pathways for the Treatment of Cancer

  2019cites this paper
• Structures of Hsp90 alpha and Hsp90 beta bound to a purine-scaffold inhibitor reveal an exploitable residue for drug selectivity.

  2019cites this paper
• Structure Based Design of a Grp94-Selective Inhibitor: Exploiting a Key Residue in Grp94 To Optimize Paralog-Selective Binding.

  2018cites this paper
• Identification and characterization of the antiplasmodial activity of Hsp90 inhibitors

  2017cites this paper
• Second Generation Grp94-Selective Inhibitors Provide Opportunities for the Inhibition of Metastatic Cancer.

  2017cites this paper
• Protein conformational flexibility modulates kinetics and thermodynamics of drug binding

  2017cites this paper
• Transformation of the Non-Selective Aminocyclohexanol-Based Hsp90 Inhibitor into a Grp94-Seletive Scaffold.

  2017cites this paper
• Modulation of Molecular Chaperones in Huntington’s Disease and Other Polyglutamine Disorders

  2016cites this paper
• Novel Tetrahydropyrido[4,3-d]pyrimidines as Potent Inhibitors of Chaperone Heat Shock Protein 90.

  2016cites this paper
• Overexpression of tumor necrosis factor receptor-associated protein 1 (TRAP1) are associated with poor prognosis of epithelial ovarian cancer

  2016cites this paper
• Paralog Specific Hsp90 Inhibitors - A Brief History and a Bright Future.

  2016cites this paper
• ATP Acyl Phosphate Reactivity Reveals Native Conformations of Hsp90 Paralogs and Inhibitor Target Engagement.

  2015cites this paper
• Hsp90 as a therapeutic target in endocrinology: current evidence

  2015cites this paper
• Towards the discovery of drug-like epigallocatechin gallate analogs as Hsp90 inhibitors.

  2014cites this paper
• Identification of novel HSP90α/β isoform selective inhibitors using structure-based drug design. demonstration of potential utility in treating CNS disorders such as Huntington's disease.

  2014cites this paper
• Selective targeting of the stress chaperome as a therapeutic strategy.

  2014cites this paper